Kymera Therapeutics公布KT-621的第一阶段B临床试验取得积极结果,该药为首个口服Stat6降解剂,适用于中重度特应性皮炎患者
Kymera Therapeutics公布KT-621的第一阶段B临床试验取得积极结果,该药为首个口服Stat6降解剂,适用于中重度特应性皮炎患者
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.